CONTENTS

Preface ............................................................................................................................ v
Contributors ................................................................................................................... ix

PART I. A REVIEW

1 The Current Status of Tumor Targeting: A Review ......................... 3
   Tarunendu Ghose

2 Clinical Applications of Targeted Therapeutics ......................... 79
   Tarunendu Ghose

PART II. TARGETING TUMORS WITH DRUG ANTIBODY CONJUGATES

3 Targeting the CD22 Receptor with RNA Damaging Agents ...... 109
   Huaitian Liu, Dianne L. Newton, Hans J. Hansen,
   Stanislaw M. Mikulski, David M. Goldenberg,
   Edward A. Sausville, and Susanna M. Rybak

4 The Development of Liposomes for Enhanced Delivery
   of Chemotherapeutics to Tumors ............................................. 119
   Paul Tardi, Ludger Ickenstein, Marcel Bally,
   and Lawrence Mayer

5 Overcoming Multiple Drug Resistance
   with Anti-Pgp Carrier ............................................................. 137
   Brigitte Pagé and Michel Pagé

6 Targeting with Transferrin ............................................................. 151
   Mandip Singh

7 Synthesis and Evaluation of Paclitaxel Immunoconjugate
   with Antitumor Activity In Vitro ............................................. 165
   Jairo Jaime Correa and Michel Pagé

8 The Use of Drug-Monoclonal Antibody Conjugates for the
   Treatment of Cancer ............................................................. 179
   Geoffrey A. Pietersz and Ian F. C. McKenzie

PART III. TARGETING TUMORS WITH ANTIBODIES

9 Targeting Vascular Endothelium with Antibodies .................. 199
   Przemek Twardowski and Kim Margolin

10 Targeting B-Cell Non-Hodgkin’s Lymphoma
    with Monoclonal Antibodies .............................................. 211
    Christian Buske and W. Hiddemann

11 From Bench to Bedside: Development of Rituximab
    (Rituxan®), A Monoclonal Antibody for the Therapy
    of Non-Hodgkin’s Lymphoma .............................................. 225
    Roland Newman

12 Mylotarg: The First Antibody-Targeted Chemotherapy Agent ... 239
    Philip R. Hamann and Mark S. Berger

vii
PART IV. TARGETING TUMORS WITH RADIOIMMUNOCONJUGATES

13 188Rhenium-Labeled Trisuccin-∆CH2HUCC49 as a Radioimmunotherapy Model in Nude Mice ............... 257
   Ahmad Safavy and Donald J. Buchsbaum

PART V. TARGETING TUMORS WITH IMMUNOTOXINS

14 General Approach for Targeting Toxins ................................. 279
   Manish Monga, Richard A. Messmann, and Edward A. Sausville

15 Antibody-Toxin Conjugates: Chemistry of Coupling and Purification ................................................................. 289
   Silvana Canevari, Maria Ines Colnaghi, Luigi Cattel, and Franco Dosio

16 Shiga-Like Toxins as Targeted Anticancer Agents ....................... 307
   Paul LaPointe and Jean Gariépy

PART VI. TARGETING TUMORS WITH ANTIBODY-ENZYME CONJUGATES (ADEPT)

17 Antibody-Directed Enzyme Prodrug Therapy with Carboxypeptidase G2: Clinical Studies ....................... 321
   Kenneth D. Bagshawe

PART VII. PHOTODYNAMIC THERAPY

18 Photodynamic Therapy: Targeting Cancer Cells with Photosensitizer-Bioconjugates ..................... 329
   Cynthia M. Allen, Wesley M. Sharman, and Johan E. van Lier

19 Tumor Targeting Using PEG-m-THPC for Photodynamic Therapy in a Rat Ovarian-Cancer Model .................... 363
   René Hornung

PART VIII. TARGETING TUMORS WITH MAGNETIC DRUGS

20 Targeting Tumors with Magnetic Drugs ............................... 379
   Andreas S. Lübbe, Christian Bergemann, and Christoph Alexiou

PART IX. PRINCIPLES AND TECHNIQUES IN TARGETING

21 Internalization of Antibodies ................................................. 391
   Jairo Jaime Correa

22 Bioconjugation and Biodistribution .................................... 411
   Francesco M. Veronese and Paulo Caliceti

23 Principles of Antitumor Targeting of Cytotoxic Drugs ................ 431
   Gene M. Dubowchik

24 Targeting by Antibody or Ligand: Which Is Better? ................... 449
   Douglas A. Lappi

Index ........................................................................................................................... 459
Tumor Targeting in Cancer Therapy
Pagé, M. (Ed.)
2002, X, 463 p. 39 illus., Hardcover
A product of Humana Press